Biocon Limited (NSEI: BIOCON)
Health Care · Biotechnology · IN
Rs349.40
-5.75% today · -1.1% 1Y
Biocon Limited (NSEI: BIOCON) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.88B and employs 16,447 people.
Over the last twelve months the share price has lost 1.1%, trading between 337.70 and 447.15.
Tweenvest scores Biocon Limited across four factors: quality 65/100, value 29/100, growth 53/100, dividend 39/100. Its strongest factor is quality.
BIOCON price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.88B
- Revenue (TTM)
- $1.83B
- P/E
- 103.78
- EPS
- 3.37
- Dividend yield
- 0.14%
- Beta (5Y)
- 0.32
- 52-week high
- Rs447.15
- 52-week low
- Rs337.70
- Avg volume (3M)
- —
- Shares outstanding
- 1.63B
- Employees
- 16,447
- Next earnings
- —
About Biocon Limited
Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.
- ISIN
- INE376G01013
- Founded
- 1978
- Listed since
- Apr 7, 2004
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| GRAIL, Inc.NasdaqGS: GRAL | $6.28B | $136.62 | -2.82% |
| Kodiak Sciences Inc.NasdaqGM: KOD | $6.26B | $98.84 | -1.03% |
| Rhythm Pharmaceuticals, Inc.NasdaqGM: RYTM | $6.25B | $90.75 | -0.03% |
| Kiniksa Pharmaceuticals International, plcNasdaqGS: KNSA | $6.22B | $80.31 | +0.66% |
| CG Oncology, Inc.NasdaqGS: CGON | $5.66B | $63.58 | -0.38% |
| Erasca, Inc.NasdaqGS: ERAS | $5.61B | $15.63 | -2.53% |
| Mirum Pharmaceuticals, Inc.NasdaqGM: MIRM | $5.58B | $86.83 | +0.95% |
| Oruka Therapeutics, Inc.NasdaqCM: ABIO | $5.44B | $— | — |
Figures last refreshed Oct 11, 2026.